{"id":47463,"date":"2022-08-18T23:02:16","date_gmt":"2022-08-18T21:02:16","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/schrodinger-reports-inducement-grants-to-newly-appointed-chief-financial-officer\/"},"modified":"2022-08-18T23:02:16","modified_gmt":"2022-08-18T21:02:16","slug":"schrodinger-reports-inducement-grants-to-newly-appointed-chief-financial-officer","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/schrodinger-reports-inducement-grants-to-newly-appointed-chief-financial-officer\/","title":{"rendered":"Schr\u00f6dinger Reports Inducement Grants To Newly Appointed Chief Financial Officer"},"content":{"rendered":"
\n

NEW YORK–(BUSINESS WIRE)–Schr\u00f6dinger<\/a>, Inc. (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced the grant of inducement equity awards to the company\u2019s newly appointed chief financial officer, Geoffrey Porges, MBBS. As previously announced, Dr. Porges joined the company on August 18, 2022. The grants were approved by the compensation committee of the board of directors pursuant to a delegation by Schr\u00f6dinger\u2019s board of directors, effective as of August 18, 2022, and as inducements material to Dr. Porges acceptance of employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).\n<\/p>\n

\nThe inducement grants consisted of a nonstatutory stock option to purchase 180,000 shares of the company\u2019s common stock and performance-based restricted stock units covering an aggregate of 90,000 shares of the company\u2019s common stock. The stock options will have an exercise price of $28.55 per share, equal to the closing price of Schr\u00f6dinger\u2019s common stock on August 18, 2022. The stock option has a ten-year term and vests over four years, with 25 percent of the shares underlying the option vesting when Dr. Porges completes 12 months of continuous service measured from his employment start date, and the balance vesting in successive equal monthly installments of 1\/48 of the original number of shares upon Dr. Porges\u2019s completion of each additional month of service over 36 months following the first anniversary of his employment start date, subject to continued service. Each performance-based restricted stock unit represents a contingent right to receive one share of the company\u2019s common stock upon the achievement of specified performance goals related to financial performance, investor engagement and business development, subject to continued service. The inducement grants are subject to the terms and conditions of award agreements covering the grants and the company\u2019s 2021 Inducement Equity Incentive Plan.\n<\/p>\n

\nAbout Schr\u00f6dinger<\/b>\n<\/p>\n

\nSchr\u00f6dinger is transforming the way therapeutics and materials are discovered. Schr\u00f6dinger has pioneered a physics-based software platform that enables discovery of high-quality, novel molecules for drug development and materials applications more rapidly and at lower cost compared to traditional methods. The software platform is used by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. Schr\u00f6dinger\u2019s multidisciplinary drug discovery team also leverages the software platform to advance collaborative programs and its own pipeline of novel therapeutics to address unmet medical needs.\n<\/p>\n

\nFounded in 1990, Schr\u00f6dinger has over 700 employees and is engaged with customers and collaborators in more than 70 countries. To learn more, visit www.schrodinger.com<\/a> follow us on LinkedIn<\/a> and Twitter<\/a>, or visit our blog, Extrapolations.com<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nJaren Irene Madden
\n
Schr\u00f6dinger, Inc.
\n
jaren.madden@schrodinger.com<\/a>
617-286-6264\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

NEW YORK–(BUSINESS WIRE)–Schr\u00f6dinger, Inc. (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced the grant of inducement equity awards to the company\u2019s newly appointed chief financial officer, Geoffrey Porges, MBBS. As previously announced, Dr. Porges joined the company on August 18, 2022. The grants were approved by … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-47463","6":"format-standard","7":"category-industry"},"yoast_head":"\nSchr\u00f6dinger Reports Inducement Grants To Newly Appointed Chief Financial Officer - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/schrodinger-reports-inducement-grants-to-newly-appointed-chief-financial-officer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Schr\u00f6dinger Reports Inducement Grants To Newly Appointed Chief Financial Officer - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"NEW YORK–(BUSINESS WIRE)–Schr\u00f6dinger, Inc. (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced the grant of inducement equity awards to the company\u2019s newly appointed chief financial officer, Geoffrey Porges, MBBS. As previously announced, Dr. Porges joined the company on August 18, 2022. The grants were approved by ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/schrodinger-reports-inducement-grants-to-newly-appointed-chief-financial-officer\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-08-18T21:02:16+00:00\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/schrodinger-reports-inducement-grants-to-newly-appointed-chief-financial-officer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/schrodinger-reports-inducement-grants-to-newly-appointed-chief-financial-officer\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Schr\u00f6dinger Reports Inducement Grants To Newly Appointed Chief Financial Officer\",\"datePublished\":\"2022-08-18T21:02:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/schrodinger-reports-inducement-grants-to-newly-appointed-chief-financial-officer\\\/\"},\"wordCount\":450,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/schrodinger-reports-inducement-grants-to-newly-appointed-chief-financial-officer\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/schrodinger-reports-inducement-grants-to-newly-appointed-chief-financial-officer\\\/\",\"name\":\"Schr\u00f6dinger Reports Inducement Grants To Newly Appointed Chief Financial Officer - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"datePublished\":\"2022-08-18T21:02:16+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/schrodinger-reports-inducement-grants-to-newly-appointed-chief-financial-officer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/schrodinger-reports-inducement-grants-to-newly-appointed-chief-financial-officer\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/schrodinger-reports-inducement-grants-to-newly-appointed-chief-financial-officer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Schr\u00f6dinger Reports Inducement Grants To Newly Appointed Chief Financial Officer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Schr\u00f6dinger Reports Inducement Grants To Newly Appointed Chief Financial Officer - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/schrodinger-reports-inducement-grants-to-newly-appointed-chief-financial-officer\/","og_locale":"en_US","og_type":"article","og_title":"Schr\u00f6dinger Reports Inducement Grants To Newly Appointed Chief Financial Officer - Pharma Trend","og_description":"NEW YORK–(BUSINESS WIRE)–Schr\u00f6dinger, Inc. (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced the grant of inducement equity awards to the company\u2019s newly appointed chief financial officer, Geoffrey Porges, MBBS. As previously announced, Dr. Porges joined the company on August 18, 2022. The grants were approved by ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/schrodinger-reports-inducement-grants-to-newly-appointed-chief-financial-officer\/","og_site_name":"Pharma Trend","article_published_time":"2022-08-18T21:02:16+00:00","author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/schrodinger-reports-inducement-grants-to-newly-appointed-chief-financial-officer\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/schrodinger-reports-inducement-grants-to-newly-appointed-chief-financial-officer\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Schr\u00f6dinger Reports Inducement Grants To Newly Appointed Chief Financial Officer","datePublished":"2022-08-18T21:02:16+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/schrodinger-reports-inducement-grants-to-newly-appointed-chief-financial-officer\/"},"wordCount":450,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/schrodinger-reports-inducement-grants-to-newly-appointed-chief-financial-officer\/","url":"https:\/\/pharma-trend.com\/en\/schrodinger-reports-inducement-grants-to-newly-appointed-chief-financial-officer\/","name":"Schr\u00f6dinger Reports Inducement Grants To Newly Appointed Chief Financial Officer - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"datePublished":"2022-08-18T21:02:16+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/schrodinger-reports-inducement-grants-to-newly-appointed-chief-financial-officer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/schrodinger-reports-inducement-grants-to-newly-appointed-chief-financial-officer\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/schrodinger-reports-inducement-grants-to-newly-appointed-chief-financial-officer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Schr\u00f6dinger Reports Inducement Grants To Newly Appointed Chief Financial Officer"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/47463","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=47463"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/47463\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=47463"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=47463"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=47463"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}